Theodore G. Liou
( out of 10 reviews )

Theodore G. Liou, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Pulmonary, Clinic 3
50 N Medical Dr
Salt Lake City , UT 84132
801-581-7806
Get Directions

Theodore Liou, MD, is Director of the Adult CF Center at the University of Utah, Professor of Internal Medicine and Adjunct Associate Professor of Pediatrics at the University of Utah. He is triple boarded in Internal, Pulmonary and Critical Care Medicine. He has taken care of patients with a highly individualized personal touch and directed the award winning team for CF for more than seventeen years.

Dr. Liou's research interests include cystic fibrosis, sepsis, ARDS, airway inflammation, pneumonia, airway ecology and antibiotic discovery. He has landmark articles in cystic fibrosis and lung transplantation in journals including JAMA and the New England Journal of Medicine as well as articles with high impact in Lancet, the American Journal of Epidemiology, the American Journal of Respiratory and Critical Care Medicine, CHEST, the Journal of Cystic Fibrosis and others. He has been invited to speak at The Gordon Conference on Enzymes, Co-enzymes and Metabolic pathways, Mayo Clinic, McGill, Case Western, U Penn, Capitol University Beijing, Children's Hospital LA, USC, Merck, Genentech, the North American CF Conference, the International Conference of the American Thoracic Society, the American Society of Microbiology, the International Society for Heart Lung Transplantation, the Italian CF Research Foundation and the annual European CF society Meetings.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Pulmonary Disease)
American Board of Internal Medicine (Internal Medicine)
National Board of Medical Examiners
American Board of Internal Medicine (Sub: Critical Care Medicine)

Patient Rating

5.0 /5
( out of 10 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

UNIVERSITY HOSPITAL

He always takes the time to address your concerns and explain them fully

UNIVERSITY HOSPITAL

Amazing provider. 10/10 care!

UNIVERSITY HOSPITAL

Dr. Liou is amazing! I love working with him. He understands everything CF and if he doesn't or is unsure he asks everyone he can to receive a 100% confident answer. He is always so friendly and understanding. He is always putting forth and works above and beyond what he needs to. I will always trust Dr. Liou with my health 100% of the time. I cannot begin to express how wonderful he is.

UNIVERSITY HOSPITAL

Dr. Liou is always very thorough and takes the time to explain anything he recommends and also answers all my questions. He is friendly, caring and personable.

UH HOSPITALS AND CLINICS

Kind and thoughtful

UNIVERSITY HOSPITAL

He really cares and goes above and beyond to help his patients

UNIVERSITY HOSPITAL

Dr. Liou is always professional and caring. Always concerned about what is in my best interest.

UNIVERSITY HOSPITAL

Dr. Liou is amazing. He is very caring and interested in all aspects of my life.

UNIVERSITY HOSPITAL

It is so nice to have a Doctor that actually listens. He is patient and genuinely concerned about your health.

UNIVERSITY HOSPITAL

Dr. Liou is always friendly and listens to my concerns/questions.

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Theodore Liou, MD, is Director of the Adult CF Center at the University of Utah, Professor of Internal Medicine and Adjunct Associate Professor of Pediatrics at the University of Utah. He is triple boarded in Internal, Pulmonary and Critical Care Medicine. He has taken care of patients with a highly individualized personal touch and directed the award winning team for CF for more than seventeen years.

Dr. Liou's research interests include cystic fibrosis, sepsis, ARDS, airway inflammation, pneumonia, airway ecology and antibiotic discovery. He has landmark articles in cystic fibrosis and lung transplantation in journals including JAMA and the New England Journal of Medicine as well as articles with high impact in Lancet, the American Journal of Epidemiology, the American Journal of Respiratory and Critical Care Medicine, CHEST, the Journal of Cystic Fibrosis and others. He has been invited to speak at The Gordon Conference on Enzymes, Co-enzymes and Metabolic pathways, Mayo Clinic, McGill, Case Western, U Penn, Capitol University Beijing, Children's Hospital LA, USC, Merck, Genentech, the North American CF Conference, the International Conference of the American Thoracic Society, the American Society of Microbiology, the International Society for Heart Lung Transplantation, the Italian CF Research Foundation and the annual European CF society Meetings.

Board Certification and Academic Information

Academic Departments Pediatrics -Adjunct Professor
Internal Medicine -Professor
Academic Divisions Public Health
Board Certification
American Board of Internal Medicine (Sub: Pulmonary Disease)
American Board of Internal Medicine (Internal Medicine)
National Board of Medical Examiners
American Board of Internal Medicine (Sub: Critical Care Medicine)

Education history

Undergraduate Biochemistry - University of California - Berkeley B.A.
Professional Medical Medicine - George Washington University M.D.
Internship Internal Medicine - Presbyterian-University Hospital Intern
Residency Internal Medicine - Presbyterian-University Hospital Resident
Fellowship Pulmonary/Critical Care - University of Utah School of Medicine Fellow

Selected Publications

Journal Article

  1. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC (2001). Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol, 153(4), 345-52.
  2. Wozniak CE, Lin Z, Schmidt EW, Hughes KT, Liou TG (2018). Thailandamide, a Fatty Acid Synthesis Antibiotic That Is Coexpressed with a Resistant Target Gene. Antimicrob Agents Chemother, 62(9).
  3. Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, Carveth H, Young DC (2018). Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrob Agents Chemother, 62(10).
  4. Liou TG, Campbell EJ (1995). Nonisotropic enzyme--inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. Biochemistry, 34(49), 16171-7.
  5. Cirulis MM, Huston JH, Sardar P, Suksaranjit P, Wilson BD, Hatton ND, Liou TG, Ryan J (2018). Right-to-left ventricular end diastolic diameter ratio in severe sepsis and septic shock. Journal of critical care, 48, 307-310.
  6. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon M (2010). Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest, 137(2), 376-87.
  7. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group (2012). Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest, 142(3), 718-724.
  8. Jensen JL, Jones CR, Kartsonaki C, Packer KA, Adler FR, Liou T (2017). Sleep Phase Delay in Cystic Fibrosis: A Potential New Manifestation of Cystic Fibrosis Transmembrane Regulator Dysfunction. Chest, 152(2), 386-393.
  9. Liou T (2019). The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease. Chest, 155(3), 605-616.
  10. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon M (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122(2), 164-72.
  11. Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR, Liou T (2018). Microbial Interactions in the Cystic Fibrosis Airway. Journal of clinical microbiology, 56(8),
  12. Liou TG, Campbell E (1996). Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. Journal of immunology (Baltimore, Md., 157(6), 2624-31.
  13. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan W (2005). Epidemiology of cystic fibrosis-related diabetes. The Journal of pediatrics, 146(5), 681-7.
  14. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, Marshall B (2001). Survival effect of lung transplantation among patients with cystic fibrosis. JAMA, 286(21), 2683-9.
  15. Liou TG, Adler FR, Cox DR, Cahill B (2007). Lung transplantation and survival in children with cystic fibrosis. The New England journal of medicine, 357(21), 2143-52.
  16. Marshall BC, Henshaw C, Evans DA, Bleyl K, Alder S, Liou T (2002). Influenza vaccination coverage level at a cystic fibrosis center. Pediatrics, 109(5), E80-0.
  17. Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, Elstad MR, Campbell EJ, Troyer BE, Whatley RE, Liou TG, Samuelson WM, Carveth HJ, Hinson DM, Morris SE, Davis BL, Day R (1998). Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. American journal of respiratory and critical care medicine, 157(5 Pt 1), 1372-80.
  18. Liou TG, Adler FR, Huang (2005). Use of lung transplantation survival models to refine patient selection in cystic fibrosis. American journal of respiratory and critical care medicine, 171(9), 1053-9.
  19. Liou TG, Adler FR, Argel N, Asfour F, Brown PS, Chatfield BA, Daines CL, Durham D, Francis JA, Glover B, Heynekamp T, Hoidal JR, Jensen JL, Keogh R, Kopecky CM, Lechtzin N, Li Y, Lysinger J, Molina O, Nakamura C, Packer KA, Poch KR, Quittner AL, Radford P, Redway AJ, Sagel SD, Sprandel S, Taylor-Cousar JL, Vroom JB, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN, Cox D (2019). Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC medical research methodology, 19(1), 88.
  20. Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, Wagener J (2010). Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of cystic fibrosis, 9(4), 250-6.
  21. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, Walsh W, Packer K, Clark T, Carveth H, Chen J, Rogers SL, Lane C, Moore J, Sturrock A, Paine R 3rd, Cox DR, Hoidal J (2012). Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PloS one, 7(8), e42748.
  22. Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG, Ortega VE, Peters SP, Hoffman EA, Buhr RG, Dolezal BA, Tashkin DP, Liou TG, Bateman LA, Schroeder JD, Martinez FJ, Barr RG, Hansel NN, Comellas AP, Rennard SI, Arjomandi M, Paine Iii (2022). Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic obstructive pulmonary diseases (Miami, Fla.), 9(2), 111-121.
  23. Liou TG, Kartsonaki C, Keogh RH, Adler F (2020). Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. Scientific reports, 10(1), 6602.
  24. McGarry LJ, Bhaiwala Z, Lopez A, Chandler C, Pelligra CG, Rubin JL, Liou T (2023). Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data. PloS one, 18(4), e0283479.
  25. Mendoza DL, Pirozzi CS, Crosman ET, Liou TG, Zhang Y, Cleeves JJ, Bannister SC, Anderegg WRL, Robert P 3r (2020). Impact of low-level fine particulate matter and ozone exposure on absences in K-12 students and economic consequences. Environmental research letters, 15(11),
  26. Szczesniak R, Andrinopoulou ER, Su W, Afonso PM, Burgel PR, Cromwell E, Gecili E, Ghulam E, Goss CH, Mayer-Hamblett N, Keogh RH, Liou TG, Marshall B, Morgan WJ, Ostrenga JS, Pasta DJ, Stanojevic S, Wainwright C, Zhou GC, Fernandez G, Fink AK, Schechter M (2023). Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations. Annals of the American Thoracic Society,
  27. Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier A (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. Journal of cystic fibrosis,

Editorial

  1. Helms MN, Liou T (2022). Spotlighting "Neutrophil Elastase Triggers the Release of Macrophage Extracellular Traps": A New Catch in Cystic Fibrosis?. American journal of respiratory cell and molecular biology, 66(1), 5-7.

Letter

  1. Liou TG, Adler FR, Cahill B (2005). Testing lung function decline to time lung transplantation. Chest, 128(1), 472-3; author reply 473-4.
  2. Liou TG, Adler FR, Hatton N (2021). The Uncertain Role of Corticosteroids in the Treatment of COVID-19. JAMA internal medicine, 181(1), 139-140.

News & Podcasts

News